PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
0.02
OCF/share of 0.02 while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if modest cash generation can build a stronger lead.
-0.07
Negative FCF/share while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would question if the business is too capex-heavy.
492.28%
Capex/OCF ratio of 492.28% while the Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would confirm if minimal reinvestment is enough for advantage.
1.71
Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 0.64. Joel Greenblatt would see if robust OCF is a recurring trait.
34.89%
OCF-to-sales ratio of 34.89% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest advantage in actually generating some cash.